A Randomized, Double-blind, Placebo-controlled, First-in-human, Study of Orally Administered AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study in Healthy Subjects

Trial Profile

A Randomized, Double-blind, Placebo-controlled, First-in-human, Study of Orally Administered AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs AL 794 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Alios BioPharma
  • Most Recent Events

    • 10 Oct 2017 Status changed from recruiting to completed.
    • 24 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
    • 24 Feb 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top